Phospho-CXCR4 (Ser339) Antibody #59028
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 45-60 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Phospho-CXCR4 (Ser339) Antibody recognizes endogenous levels of CXCR4 protein only when phosphorylated at Ser339. This antibody does not cross-react with CXCR4 protein when phosphorylated at Ser324 or Ser325.
Species Reactivity:
Human
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Mouse, Hamster, Chicken
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser339 of human CXCR4 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
CXCR4 is a chemokine receptor that belongs to the G protein-coupled receptor family. It is activated by a small cytokine, CXCL12, also known as stromal cell derived factor 1 (SDF1) (1). The main function of CXCR4 is the mediation of the homing of progenitor cells in the bone marrow and their recruitment to sites of injury (2). More recently, CXCR4 has been studied as a potential therapeutic target in the context of autoimmune diseases (3), as well as cancer, as the receptor is involved in the regulation of migration, proliferation, and survival of cancer cells (4).
CXCR4 is phosphorylated at Ser339 by G protein-coupled receptor kinase 6 upon treatment of cells with CXCL12 (5). Phosphorylation of CXCR4 at Ser339 has also been observed following epidermal growth factor and phorbol ester treatment (6). TCR-mediated transactivation of CXCR4 at Ser339 activates a PREX1-Rac1-signaling pathway that stabilizes interleukin-2, -4, and -10 messenger RNA transcripts (7).
- Blanchet, X. et al. (2012) Front Immunol 3, 175.
- Döring, Y. et al. (2014) Front Physiol 5, 212.
- Debnath, B. et al. (2013) Theranostics 3, 47-75.
- Teicher, B.A. and Fricker, S.P. (2010) Clin Cancer Res 16, 2927-31.
- Busillo, J.M. et al. (2010) J Biol Chem 285, 7805-17.
- Woerner, B.M. et al. (2005) Cancer Res 65, 11392-9.
- Kremer, K.N. et al. (2017) Blood 130, 982-994.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.